Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Neha Korde

Showing results (81-90 of 125) with videos related to

Pageof 13
Sort By:
Research Square|February 26, 2024
Comparison of Infectious Complications with BCMA-directed Therapies in Multiple MyelomaAlexander Lesokhin, Karthik Nath, Tala Shekarkhand, et al.
Blood Advances|January 4, 2018
Baseline mutational patterns and sustained MRD negativity in patients with high-risk smoldering myelomaSham Mailankody, Dickran Kazandjian, Neha Korde, et al.
Blood Neoplasia|June 27, 2025
Belantamab mafodotin in patients with relapsed/refractory multiple myeloma: a real-world experienceMalin Hultcrantz, Andriy Derkach, Hani Hassoun, et al.
Blood Cancer Journal|May 27, 2024
Prognostic impact of corticosteroid and tocilizumab use following chimeric antigen receptor T-cell therapy for multiple myelomaBruno Almeida Costa, Jessica Flynn, Noriko Nishimura, et al.
Blood Advances|April 15, 2024
Unscheduled health care interactions in patients with multiple myeloma receiving T-cell redirection therapiesAnna J Howard, Isabel Concepcion, Alice X Wang, et al.
Blood|May 10, 2024
Antigen escape as a shared mechanism of resistance to BCMA-directed therapies in multiple myelomaRoss S Firestone, Nicholas D Socci, Tala Shekarkhand, et al.
Blood Cancer Journal|April 21, 2022
Nutrition perceptions, needs and practices among patients with plasma cell disordersMaria A Malik, Nathan W Sweeney, Mohammad Jafri, et al.
Clinical Lymphoma, Myeloma & Leukemia|April 26, 2026
Low Dose Tocilizumab for Mitigation of Cytokine Release Syndrome With T-Cell Engaging Bispecific AntibodiesIssam S Hamadeh, Maximillian Merz, Andriy Derkach, et al.
Blood Cancer Journal|November 2, 2025
Cytomegalovirus reactivation during treatment with bispecific antibodies for relapsed/refractory multiple myelomaEric Jurgens, Tala Shekarkhand, Colin Rueda, et al.
Blood Cancer Journal|April 12, 2026
Functionally high-risk disease is associated with poor outcomes after late-line CAR T-cell therapy for multiple myelomaHamza Hashmi, Tara Sebastian, Sridevi Rajeeve, et al.
Pageof 13

Showing results (81-90 of 125) with videos related to

Sort By:
Pageof 13
Research Square|February 26, 2024
Comparison of Infectious Complications with BCMA-directed Therapies in Multiple MyelomaAlexander Lesokhin, Karthik Nath, Tala Shekarkhand, et al.
Blood Advances|January 4, 2018
Baseline mutational patterns and sustained MRD negativity in patients with high-risk smoldering myelomaSham Mailankody, Dickran Kazandjian, Neha Korde, et al.
Blood Neoplasia|June 27, 2025
Belantamab mafodotin in patients with relapsed/refractory multiple myeloma: a real-world experienceMalin Hultcrantz, Andriy Derkach, Hani Hassoun, et al.
Blood Cancer Journal|May 27, 2024
Prognostic impact of corticosteroid and tocilizumab use following chimeric antigen receptor T-cell therapy for multiple myelomaBruno Almeida Costa, Jessica Flynn, Noriko Nishimura, et al.
Blood Advances|April 15, 2024
Unscheduled health care interactions in patients with multiple myeloma receiving T-cell redirection therapiesAnna J Howard, Isabel Concepcion, Alice X Wang, et al.
Blood|May 10, 2024
Antigen escape as a shared mechanism of resistance to BCMA-directed therapies in multiple myelomaRoss S Firestone, Nicholas D Socci, Tala Shekarkhand, et al.
Blood Cancer Journal|April 21, 2022
Nutrition perceptions, needs and practices among patients with plasma cell disordersMaria A Malik, Nathan W Sweeney, Mohammad Jafri, et al.
Clinical Lymphoma, Myeloma & Leukemia|April 26, 2026
Low Dose Tocilizumab for Mitigation of Cytokine Release Syndrome With T-Cell Engaging Bispecific AntibodiesIssam S Hamadeh, Maximillian Merz, Andriy Derkach, et al.
Blood Cancer Journal|November 2, 2025
Cytomegalovirus reactivation during treatment with bispecific antibodies for relapsed/refractory multiple myelomaEric Jurgens, Tala Shekarkhand, Colin Rueda, et al.
Blood Cancer Journal|April 12, 2026
Functionally high-risk disease is associated with poor outcomes after late-line CAR T-cell therapy for multiple myelomaHamza Hashmi, Tara Sebastian, Sridevi Rajeeve, et al.
Pageof 13